Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 30, 2019

View Archived Issues

New phase I study of SGN-CD228A enrolls patients with select advanced solid tumors

Enrollment ongoing in phase II study of JNJ-61393215 for the treatment of depression

Pfizer announces topline results from pivotal JADE MONO-2 study of abrocitinib

Sanofi initiates phase II study of SAR-439859 in metastatic ER-positive breast cancer

Second phase III trial of AVP-786 for agitation in Alzheimer's dementia misses endpoints

Anchoring protein is potential biomarker, target for Parkinson's disease

Phase I data presented on ADCT-601 in patients with advanced solid tumors

Antithrombin isoform protects against sepsis

Emergent BioSolutions, Indivior win NIH grants to study drugs for opioid use disorder

WX-0593 shows antitumor activity in ALK/ROS1-positive NSCLC

ESMO 2019: Immunity is local phenomenon, for better and for worse

Zoliflodacin begins pivotal phase III trial for treatment of gonorrhea

Phase IIa data support S-600918 as promising option for refractory chronic cough

Arcus Biosciences divulges ARG1 and ARG2 inhibitors

Medivir discloses nucleoside analogues for leukemia

Southwest Research Institute patent details agents for filovirus infection

Development and characterization of IRAK-4 inhibitors

Bristol-Myers Squibb synthesizes hSTING agonists

Novel near-infrared probe of biliary anatomy for image-guided hepatic surgery

New TRPC5 modulators patented by Goldfinch Biopharma

Safety characterization of a sapM mutated-BCG vaccine

FDA approves Rituxan for pediatric granulomatosis with polyangiitis and microscopic polyangiitis

New variants in VPS13C gene tied to reduced risk of Parkinson's disease

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...